Adlai Nortye ADR
web2Adlai Nortye is a clinical stage biopharmaceutical company developing experimental cancer thera...
About
Adlai Nortye is a clinical stage biopharmaceutical company developing experimental cancer therapies, with American depositary shares representing ownership interests in its listed holding company. Its research focuses on treatments targeting cancer signaling pathways and mechanisms that influence immune responses to tumors. Its development portfolio includes AN9025, an oral RAS inhibitor, AN4035, an antibody drug conjugate, and AN8025, an investigational immunotherapy. The company conducts clinical development activities involving patients in multiple jurisdictions and collaborates with research and pharmaceutical organizations. Its American depositary shares trade on Nasdaq under ANL, while its investigational treatments remain subject to clinical testing and regulatory evaluation.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
Adlai Nortye ADR profile.
Expert coverage
No published expert evaluations are available for this project yet.
Orbitrum Academy